News

The event will bring together patients, care partners, allied personnel, and medical professionals to speak directly with their elected officials to discuss a variety of vision and eye health issues

Ophthalmologists could find themselves treating a growing number of young people who are applying lip balm to their eyelids, only to experience discomfort and vision issues when it gets into their eyes.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Key is to use stem cell treatments to ensure optimal outcomes for patients.

According to James Chodosh MD, MPH, some corneal conditions may not be treatable with a transplant.

At the American Glaucoma Society meeting in Austin, Texas, the company presented findings demonstrating the safety and efficacy of its FLigHT treatment.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Priya M. Mathews, MD, MPH discusses ophthalmology and what she wishes she knew to start her career. As well as tips for other ophthalmologists who are just starting their careers.

The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism using the SILK Procedure.

Despite its promise, RGC replacement represents a more formidable challenge.

When tested, the recalled Artificial Tears used by the firefighter were found to contain large amounts of Pseudomonas Aeruginosa bacterial contamination.

Joel S. Schuman, MD, FACS, is a pioneer in the field of ophthalmology, lauded for his research, discoveries, inventions, and compassionate patient care over the course of his more than 30-year career.

The company is anticipating the first patient-first visit in Q1 2023 and is looking to release top-line data from the Phase 2 trial in Q4 2023.

The regulatory milestone fulfills the company’s goal to file the IND for OCU200 within the first quarter of 2023.

David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Eye care providers must look beyond visual acuity in screening for disease.

Artificial intelligence (AI) with ultra-widefield fundus autofluorescence images may be helpful to objectively estimate progression of retinitis pigmentosa (RP) and visual function.

Dr. Jai Parekh, a clinical associate professor of Ophthalmology/The New York Eye & Infirmary of the Mount Sinai School of Medicine and David Hutton, Managing Editor of Opthalmology Times discuss the importance of ocular health prior to cataract and refractive surgery, specifically with osmolarity testing.

The company’s iDose TR is a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.

Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.

The Cardinal Health study reveals provider perceptions of commercially available biosimilars and anticipated launches, which have the potential to increase equitable access to critical treatments.

Outcomes achieved with information, osmolarity testing, proven treatments

The study compared 126 IOL injectors of 13 IOL injector systems regarding the manufacturers’ recommended preoperative incision sizes to evaluate the intraoperative incision enlargement and postoperative incision sizes.

The Alteogen Inc. subsidiary company provided an update on its ALT-L9 biosimilar to compete with EYLEA

A comparison of Hoya Vivinex and Alcon AcrySof lenses evaluated the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed.

SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.

Data shows the Notal Vision Home OCT device can be used to manage wet age-related macular degeneration (AMD).

The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.

The latest IOLs offer an improvement in stray light performance and enhanced contrast.